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Background
Monitoring in randomized trials is recommended as
part of International Conference on Harmonisation -
Good Clinical Practice standards. On-site monitoring in
multicentre trials is common but is costly and can be
inefficient. Central statistical monitoring can be used to
detect unusual data patterns, identify intentional or
unintentional trial misconduct, and to prioritise on-site
visits and additional training. Motivated by an ongoing
international multicentre clinical trial of over 25,000
randomized participants with electronic data capture,
we developed key risk indicator (KRI) methods for cen-
tral statistical monitoring in multicentre trials.
Method and results
Statistical monitoring of KRIs such as the rate of serious
adverse event reporting, compliance with study treat-
ment visit duration (based on how long the electronic
case report form is open for) and blood results may be
informative for identifying poor site performance in ran-
domized trials. We have used these KRIs to illustrate an
approach to central statistical monitoring.
For examining the rate of serious adverse event
reporting, centres were assigned a dichotomous score
depending on whether they showed extreme deviation
from comparable sites (arbitrarily defined as half the
observed median rate across sites). A similar approach
was used to identify sites with short visit duration and
these methods were also extended to examine repeated
measurements of compliance with study treatment.
Blood results and other similar continuous variables
were examined for unusual patterns that may suggest
fabricated data or training issues. Residuals were calcu-
lated from linear regression models allowing for impor-
tant covariates. The moments of the distribution (mean,
variance, skewness and kurtosis) of the residuals within a
centre were compared with those across sites. Subse-
quently, centres were assigned a dichotomous score
depending on whether the observed data showed relevant
(clinically or otherwise) deviation from comparable sites.
Varying combinations of KRIs may be informative for
different questions of interest. For example, KRIs that
are useful for identifying potential data fabrication may
not be relevant for assessing unintentional protocol vio-
lations. Consequently, we used flexible weighting meth-
ods to formulate summary scores involving different
KRIs of interest.
Conclusions
KRI methods provide a flexible approach to central sta-
tistical monitoring in multicentre clinical trials. How-
ever, a KRI approach needs to be tailored to each study,
and the KRIs selected using knowledge of what is
important to individual clinical trials.
Published: 13 December 2011
doi:10.1186/1745-6215-12-S1-A135
Cite this article as: Elsa et al.: A key risk indicator approach to central
statistical monitoring in multicentre clinical trials: method development
in the context of an ongoing large-scale randomized trial. Trials 2011 12
(Suppl 1):A135.
Clinical Trial Service Unit and Epidemiological Studies Unit University of
Oxford, Oxford, UK
Elsa et al. Trials 2011, 12(Suppl 1):A135
http://www.trialsjournal.com/content/12/S1/A135 TRIALS
© 2011 Valdés-Márquez et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.